Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher.

Stressful childhood experiences can accelerate brain aging

Stressful or traumatic experiences in childhood have been shown to negatively impact an individual’s health as an adult. Those affected face an increased risk of illness and often suffer from depression, anxiety disorders, and cardiovascular or metabolic diseases. Until now, little has been known about whether such experiences could contribute to the development of neurodegenerative diseases.